Clinical trials: Rapid Response System
Hepatitis C, Chronic
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with…
- Trial name
- NCT01356160
- Testing
- GS-5885, GS-9451, peginterferon alfa-2a
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 351 people
- Sponsor
- Gilead Sciences
Interstitial Lung Disease, Myositis
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Idiopathic inflammatory myopathies (IIM) are a group of autoimmune conditions characterized by inflammation of muscles with possible extra-muscular manifestations which can include skin and interstitial lung disease (ILD).
- Trial name
- NCT07775235
- Testing
- Immunosuppressant Regimen
- Where
- Singapore
- Volunteers
- 80 people
- Sponsor
- Singapore General Hospital
IBD (Inflammatory Bowel Disease)
E-nose in Evaluating Colitis Activity
The goal of this observational study is to learn whether a rapid stool-based imaging test can help monitor inflammatory bowel disease (IBD) in children.
- Trial name
- SPECTROS (NCT07781215)
- Testing
- Differential Mobile Spectrometry analysis of the stool
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Primary Central Nervous System Lymphoma
Rapid Diagnosis and Treatment Response Monitoring of Primary CNS Lymphoma Using CSF ctDNA Liquid Biopsy
The incidence of primary central nervous system lymphoma (PCNSL) has increased steadily, and the disease often progresses rapidly, with many patients presenting in critical condition.
- Trial name
- NCT07851363
- Testing
- HD-MTX-based chemotherapy, BTK inhibitor
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiaohui Ren
Chronic Hepatitis C
Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
The purposes of this study are: 1. To evaluate the efficacy and safety of low-dose versus standard-dose of ribavirin in combination with peginterferon alfa-2a given for 16 weeks in hepatitis C virus (HCV) genotype 2 infected…
- Trial name
- NCT00540345
- Testing
- pegylated interferon alpha 2a and plus ribavirin, Pegylated interferon alfa-2a and ribavirin, pegylated interferon alpha 2a and ribavirin
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Pediatric ALL, Sepsis
Evaluation of Pediatric eCART Implementation
This is a study comparing 3 years of retrospective data (pre-implementation) to 2 years of prospective data after the implementation of a pediatric version of Electronic Cardiac Arrest Risk Triage (pediatric eCART), a clinical…
- Trial name
- NCT06771830
- Testing
- Pediatric eCART
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- University of Wisconsin, Madison
HCV Infection
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1…
- Trial name
- NCT00743795
- Testing
- GS-9190, Peginterferon Alfa 2a, Ribavirin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 252 people
- Sponsor
- Gilead Sciences
Stroke
MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)
Based on the results of recent randomized controlled trials, current international guidelines recommend the initiation of endovascular treatment within 6 hours of symptom onset for acute ischemic stroke.
- Trial name
- NCT02668627
- Testing
- Endovascular treatment
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Samsung Medical Center
Hepatitis C, Chronic
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.
- Trial name
- NCT00623428
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 235 people
- Sponsor
- Hoffmann-La Roche
Lupus Nephritis
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).
- Trial name
- NCT07611214
- Testing
- LUPKYNIS, belimumab, obinutuzumab or anifrolumab, mycophenolic acid analog (MPAA)
- Where
- 27 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aurinia Pharmaceuticals Inc.
Type 1 Diabetes Mellitus
Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes
This is an Open-label, randomized study in Type 1 diabetics looking at exposure and response (PK/PD) of TI using GEN2C Inhaler versus rapid acting analog.
- Trial name
- NCT01544881
- Testing
- Technosphere Insulin Inhalation Powder, Rapid Acting Analog
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mannkind Corporation
Hepatitis C Virus Infection, Response to Therapy of
Rapid HCV Treatment Access for Persons Who Use Drugs
This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP).
- Trial name
- RAPID-HCV (NCT04677153)
- Testing
- Test and treat plus peer mentors, Usual care
- Where
- 4 sites in United States, Canada
- Volunteers
- 198 people
- Sponsor
- Johns Hopkins University
Hepatitis C, Chronic
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in…
- Trial name
- NCT01371578
- Testing
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 163 people
- Sponsor
- Gilead Sciences
Sepsis, Septic Shock
Nucleosome Monitoring Relevance for Outcome Prediction in Critically Ill Patients
NUROPI is a single-centre, prospective, non-interventional study in the Intensive Care Unit (ICU) of Erasme Hospital (Hôpital Universitaire de Bruxelles, Brussels, Belgium).
- Conditions
- Sepsis, Septic Shock, Cardiac Arrest (CA), Pancreatitis
- Trial name
- NuROPI (NCT07184593)
- Testing
- Plasma H3.1 nucleosome measurement
- Volunteers
- 1,000 people
- Sponsor
- Erasme University Hospital
Hepatitis C, Chronic
A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)
This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin).
- Trial name
- NCT01429792
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Where
- 26 sites in Israel
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Comparison of Pegasys Versus Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4
Genotype 4 hepatitis C virus is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world. Although rare in western nations, genotype 4 is the most common variant of the hepatitis C virus in…
- Trial name
- NCT00502099
- Testing
- Pegylated interferon alpha 2a, Ribavirin, Pegylated interferon alpha 2 b plus ribavirin
- Volunteers
- 217 people
- Sponsor
- Amr Hafez
Metastatic Spinal Cord Compression
To Determine Whether it is Feasible to Treat Patients Requiring Urgent Radiotherapy Diagnosed With Metastatic Cord Compression (MSCC) on the Magnetic Resonance Linear Accelerator (MRL) in a Single Appointment and Compare it to the Standard of Care Radiotherapy Pathway
The goal of this clinical trial is to understand whether the Magnetic Resonance Linear Accelerator (MRL) could expedite Radiotherapy treatment for Metastatic Cord Compression (MSCC) by removing the need for a planning CT (pCT)…
- Trial name
- RESONATE (NCT06965101)
- Testing
- Radiotherapy to the spine in a single appointment
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- The Christie NHS Foundation Trust
Cardiovascular Diseases, Respiratory Diseases
Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care
The goal of this study was to identify the etiology of events and demographics of patients that experience complications requiring activation of the Rapid Response Team (RRT) during the first 24 h following anesthetic care.
- Conditions
- Cardiovascular Diseases, Respiratory Diseases, Neurologic Diseases
- Trial name
- NCT02754947
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nationwide Children's Hospital
Bacteremia
T2 and SeptiCyte RAPID Duration Project
Infection with bacteria and other germs in the blood can be deadly. How long germs stay in the blood is important for two reasons.
- Trial name
- NCT04821661
- Where
- 3 sites in Australia
- Volunteers
- 102 people
- Sponsor
- The University of Queensland
Hepatitis C
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
This study is being conducted to learn more about the safety and effect of telaprevir in combination with peginterferon alfa-2a (PEG-IFN) and ribavirin (RBV) in participants with hepatitis C who have never been treated for their…
- Trial name
- NCT00758043
- Testing
- telaprevir, ribavirin, peginterferon alfa-2a
- Where
- 82 sites in United States, Belgium and 2 more
- Volunteers
- 540 people
- Sponsor
- Vertex Pharmaceuticals Incorporated